期刊文献+

影响晚期癌症伴慢性中重度疼痛患者镇痛效果的因素分析 被引量:28

Factors influencing the analgesic effect of pain in advanced cancer patients with moderate or severe chronic pain
下载PDF
导出
摘要 目的探讨影响晚期癌症伴慢性中重度疼痛患者镇痛效果的相关因素,为晚期癌症姑息治疗提供一些参考。方法收集260例晚期恶性肿瘤伴有慢性中重度疼痛患者的相关资料,所有患者均进行规范化镇痛治疗。以疼痛强度数字分级法评分降至≤3分,爆发痛次数≤3次/日,解救治疗次数≤3次/日作为疼痛控制良好的指标,以镇痛3天疼痛控制情况、镇痛时间、镇痛药物剂量作为评价镇痛难易的指标。分析性别、年龄、肿瘤类型、有无骨转移、疼痛强度、疼痛部位、疼痛原因、疼痛机制及有无频发爆发痛(每天3次以上)对镇痛效果的影响。结果 260例患者镇痛治疗3天疼痛控制良好率为75.4%(196/260),中位镇痛时间为2天。Logistic回归及Cox回归分析结果显示,消化系统肿瘤、重度疼痛和频发爆发痛是导致镇痛3天疼痛控制不佳(P<0.05)及镇痛时间长(P<0.05)的独立危险因素,而性别、年龄、骨转移、疼痛部位、疼痛原因和疼痛机制对镇痛3天疼痛控制情况及镇痛时间长短无显著影响(P>0.05)。185例应用强阿片类药物患者中,年龄<60岁(P=0.018)、重度疼痛(P<0.001)、存在神经病理性疼痛(P=0.002)及频发爆发痛(P=0.015)的患者需止痛药物剂量大,而性别、肿瘤类型、骨转移、疼痛部位、疼痛原因对镇痛药物剂量无显著影响(P>0.05)。结论年龄<60岁、消化系统肿瘤、重度疼痛、存在神经病理性疼痛及频发爆发痛为影响镇痛效果的危险因素。 Objective To analyze the factors influencing the analgesic effect of pain in advanced cancer patients with moder-ate or severe chronic pain, and provide some references to palliative care for advanced cancer patients. Methods Data were collected from 260 advanced cancer patients with moderate or severe chronic pain. All the patients received standard analgesic treatment. Pain in-tensity numerical rating scale( NRS)≤3, breakthrough pain≤3 times/day, salvage treatment number≤3 times/day were used as the indicators of good pain control. Pain control after 3 days-treatment, the analgesic time and analgesic doses needed for stable pain con-trol were chosen as the evaluation indicators of analgesic complexity. The influences of following factors on the analgesic effects were an-alyzed, including gender, age, type of tumor, having bone metastases or not, pain intensity, pain location, pain causes, pain mecha-nism and having frequent breakthrough pain( more than 3 times a day) or not. Results In this study, 75?4% of the 260 patients had good pain control( NRS≤3) in 3 days, and the median analgesic time was two days. Logistic regression and Cox regression analyses showed that digestive system carcinoma, severe pain and frequent breakthrough pain were independent risk factors of poorer pain control in 3 days(P value were 0?032,〈0?001,〈0?001, respectively), and also needed longer time for stable pain control(P value were 0?042, 0?002, 0?013, respectively) , while gender, age, bone metastases, pain location, pain causes and pain mechanism had no re-lationship with 3 days-pain control and the time of analgesia( P〉0?05) . Of 185 patients who used strong opioids, patients younger than 60 years old(P=0?018), or those with severe pain(P〈0?001), neuropathic pain(P=0?002), frequent breakthrough pain(P=0?015) needed more analgesic drugs, while gender, type of tumor, bone metastases, pain causes and pain location had nothing to do with the analgesic doses( P〉0?05) . Conclusion Younger than 60 years old, digestive system carcinoma, severe pain, neuropathic&nbsp;pain and frequent breakthrough pain were risk factors of pain control.
出处 《临床肿瘤学杂志》 CAS 2016年第3期251-256,共6页 Chinese Clinical Oncology
关键词 晚期癌症 癌痛 疼痛强度 爆发痛 神经病理性疼痛 Advanced cancer Cancer pain Pain intensity Breakthrough pain Neuropathic pain
  • 相关文献

参考文献1

二级参考文献12

  • 1Merskey H:Logic,truth and language in concepts of pain.Qual Life Res,1994,3(Suppl 1):S69-76.
  • 2Augusto Caraceni,Emesto Zecca,Cesare Bonezzi,et al.Gabapentin for Neuropathic Cancer Pain:A Randomized Controlled Trial from the Gabapentin Cancer Pain Study Group.J Clin Oncology,2004,22:2909-2917.
  • 3Cherny NI,Thaler HT,Friedlander-Klar H,et al.Opioid responsiveness of cancer pain syndromes caused by neuropathie or nociceptive mechanisms:A combined analysis of controlled,single-dose studies.Neurology,1994,44:857-861.
  • 4Field MJ,Li Z,Sehwarz JB.Ca2+channel alpha2delta ligands for the treatment of neuropathic pain.J Med Chem,2007,50:2569-2575.
  • 5Gilron I,Bailey JM,Tu D,et al.Morphine,gabapentin,or their combination for neuropathic pain.N Engl J Med,2005,352:1324-1334.
  • 6Rice AS,Maton S.Postherpetic Neuralgia Study Group.Gabapentin in postherpetic neuralgia:a randomised,double blind,placebo controlled study.Pain,2001,94:215-224.
  • 7Morello CM,Leckband SG,Stoner CP,et al.Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain.Arch Intern Med,1999,159:1931-1937.
  • 8Gordh TE,Stubhaug A,Jensen TS,et al.Gabapentin in traumatic nerve injury pain:a randomized,double-blind,placebo-controlled,cross-over,multi-center study.Pain,2008,138:255-266.
  • 9Keskinbora K,Pekel AF,Aydinli I.Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain:a randomized open trial..J Pain Symptom Manage,2007,34:183-189.
  • 10Fan BF.Postmarketing surveillance study of Oxycodoue tablets for relieving moderate to severe postherpetic neuralgia pain.Oncology,2008,74 Suppl 1:66-71.

共引文献44

同被引文献225

引证文献28

二级引证文献193

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部